周 倩 博士 副研究員 博士生/碩士生導師
郵 箱:zhouqian@hainanu.edu.cn
1.教育背景
2017.08—2022.06,中山大學, 藥物化學,理學博士;
2013.08—2017.06,中山大學, 藥學,理學學士;
2.科研情況
課題組以磷酸二酯酶為靶标,結合海南豐富獨特的黎藥與海洋藥物資源,進行新型PDE小分子抑制劑開發、适應症探索以及機制研究。目前已在Acta Pharm Sin B, J Med Chem, Chinese Chem Lett, J. Enzym. Inhib. Med. Chem.等SCI期刊發表論文20餘篇,其中以通訊/第一作者發表文章10餘篇。申請專利10餘項,其中授權8項。
3. 研究方向
靶向神經炎症的抗神經退行性疾病的創新藥物研究
靶向PDE的抗纖維化藥物發現與分子機制研究
4. 項目
[1] 國家自然科學基金委員會,青年科學基金項目,2024-01至2026-12,在研,主持
[2] 海南大學科研啟動基金項目,2022-11至2027.11,在研,主持
[3] 海南省自然科學基金面上項目,2024.01.01-2026.12.31,主持
5. 代表性成果
[1] Zhexin Chen#, Yuqing Shi#, Fang Zhong, Kai Zhang, Furong Zhang, Shenghong Xie, Zhongbin Cheng, Qian Zhou*, Yi-You Huang*, Hai-Bin Luo*. Discovery of amentoflavone as a natural PDE4 inhibitor with anti-fibrotic effects[J]. Chinese Chemical Letters, 2025, 36(4): 109956.
[2] Yi-You Huang#, Xiang Luo#, Kai Zhang#, Yulan Liang, Furong Zhang, Guochao Liao, Shenghong Xie, Pei-Luo Huang, Siyu Hou, Qian Zhou*, Yong Zou*, Hai-Bin Luo*. Structure-based optimization of isoaurostatin as novel PDE4 inhibitors with anti-fibrotic effects[J]. Chinese Chemical Letters, 2024, Doi: 10.1016/j.cclet. 2024.110586.
[3] Mei-Yan Jiang, Chen Zhang, Qing-Hua Huang, Ling-Ling Feng, Yi-Yi Yang, Qian Zhou*, Hai-Bin Luo*, Yinuo Wu*. Discovery of Selective PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects by Targeting the Metal Pocket[J]. Journal of Medicinal Chemistry, 2024, 67(22): 20203-20213.
[4] Sen Wang #, Guofeng Yang #, Kai Zhang #, Zhexin Chen, Meiying Qiu, Siyu Hou, Tiansheng Zheng, Zongmin Wu, Qinjiang Ma, Furong Zhang, Ge Gao, Yi-You Huang, Qian Zhou*, Hai-Bin Luo*, Deyan Wu*. Structural optimization of Moracin M as novel selective phosphodiesterase 4 inhibitors for the treatment of idiopathic pulmonary fibrosis[J]. Bioorganic Chemistry, 2024, 149, 107474.
[5] Qian Zhou#, Mei-Ling Le #, Yiyi Yang, Wenjuan Wang, Yuqi Huang, Quan Wang, Yijing Tian, Meiyan Jiang, Yong Rao*, Hai-Bin Luo*; Yinuo Wu*; Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axis, Acta Pharmaceutica Sinica B, 2023. 13(3): 1180-1191.
[6] Qian Zhou#, Wei-Hao Luo#, Bei Zhang#, Zhao-Hang Xue, Qing-Hua Huang, Ling-Ling Feng, Yinuo Wu*, Chen Zhang*. Design, synthesis, and evaluation of quinolin-2(1H)-ones as PDE1 inhibitors for the treatment of inflammatory bowel disease[J]. Bioorganic Chemistry, 2025, 154:107979.
[7] Xu-Nian Wu#, Qian Zhou#, Ya-Dan Huang, Xi Xie, Zhe Li, Yinuo Wu, Hai-Bin Luo*. Structure-Based Discovery of Orally Efficient Inhibitors via Unique Interactions with H-pocket of PDE8 for the Treatment of Vascular Dementia[J]. Acta Pharmaceutica Sinica B, 2022, 12(7): 3103-3112.
[8] Yuncong Yang#, Sirui Zhang#, Qian Zhou#, Chen Zhang, Yuqi Gao, Hao Wang, Zhe Li, Deyan Wu, Yinuo Wu, Yi-You Huang*, Lei Guo*, Hai-Bin Luo*. Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension[J]. Acta Pharmaceutica Sinica B, 2020, 10(12): 2339-2347.
[9] Yadan Huang#, Xu-Nian Wu#, Qian Zhou#, Yinuo Wu, Dongxiao Zheng, Zhe Li, Lei Guo, Hai-Bin Luo*. Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors[J]. Journal of Medicinal Chemistry, 2020, 63(24):15852-15863.
[10] Jinhao Liang#, Yi-You Huang#, Qian Zhou#, Yuqi Gao, Zhe Li, Deyan Wu, Si Yu, Lei Guo, Zhen Chen, Ling Huang, Steven H Liang, Xixin He*, Ruibo Wu*, Hai-Bin Luo*. Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia[J]. Journal of Medicinal Chemistry, 2020, 63(6): 3370–3380.
[11] Yinuo Wu#, Qian Zhou#, Tianhua Zhang#, Zhe Li, Yi-Ping Chen, Pei Zhang, Yan-Fa Yu, Haiju Geng, Yi-Jing Tian, Chen Zhang, Yu Wang, Jian-Wen Chen*, Yan Chen*, Hai-Bin Luo*. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia[J]. Journal of Medicinal Chemistry, 2019, 62:4218-4224.
[12] Mei-Ling Le, Yi-Yi Yang, Mei-Yan Jiang, Chuan Han, Zhi-Rong Guo, Run-Duo Liu, Zheng-Jiong Zhao, Qian Zhou*, Shijun Wen*, Yinuo Wu*. Discovery of novel selective phosphodiesterase‑1 inhibitors for the treatment of acute myelogenous leukemia[J]. Bioorganic Chemistry, 2024, 144:107114.
[13] Chen Zhang#, Qian Zhou #, Xu-Nian Wu, Ya-Dan Huang, Jie Zhou, Zengwei Lai*, Yinuo Wu*, Hai-Bin Luo. Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer's disease[J]. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33(1):260-270.
[14] 周倩, 侯思宇, 羅海彬, 郇婉婷, 張锴, 謝聖弘. 用于降低尿酸水平的磷酸二酯酶5型抑制劑及其用途, 2024-05-28,中國, 118079003A.
[15] 羅海彬, 周倩, 侯思宇, 郇婉婷, 張锴. 降低尿酸和/或預防尿酸升高的中藥及其制備方法和應用, 2024-05-28,中國, 118078872A.
[16] 羅海彬, 周倩, 盧明偉, 侯思宇, 張锴, 吳德燕. 預防和/或治療高尿酸血症的中藥複方及制備方法和應用, 2024-07-19, 中國, 118356448A .
[17]羅海彬; 吳旭年; 黃雅丹; 周倩; 一種2-氯腺嘌呤衍生物、制備方法及應用, 2022-03-25, 中國, CN202011126602.3.
[18]羅海彬; 黃儀有; 李哲; 周倩; 托芬那酸或其藥學上可接受的鹽在制備預防和/或治療新型冠狀病毒炎症藥物中的應用, 2022-02-01, 中國, CN202010105310.5.
[19]羅海彬; 吳一諾; 張佩; 周倩; 陳儀萍; 張天華; 于豔發; 吳旭年; 一類N-取代吡唑并[3,4-d]嘧啶酮類化合物及其制備方法和應用, 2021-05-14, 中國, CN201810858465.9.